Matches in Wikidata for { <http://www.wikidata.org/entity/Q89242804> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- Q89242804 description "artículu científicu espublizáu n'ochobre de 2014" @default.
- Q89242804 description "im Oktober 2014 veröffentlichter wissenschaftlicher Artikel" @default.
- Q89242804 description "scientific article published on 26 October 2014" @default.
- Q89242804 description "wetenschappelijk artikel" @default.
- Q89242804 description "наукова стаття, опублікована в жовтні 2014" @default.
- Q89242804 name "Ranibizumab for the Treatment of Visual Impairment Due to Myopic Choroidal Neovascularization: Cost-Effectiveness Versus Aflibercept" @default.
- Q89242804 name "Ranibizumab for the Treatment of Visual Impairment Due to Myopic Choroidal Neovascularization: Cost-Effectiveness Versus Aflibercept" @default.
- Q89242804 type Item @default.
- Q89242804 label "Ranibizumab for the Treatment of Visual Impairment Due to Myopic Choroidal Neovascularization: Cost-Effectiveness Versus Aflibercept" @default.
- Q89242804 label "Ranibizumab for the Treatment of Visual Impairment Due to Myopic Choroidal Neovascularization: Cost-Effectiveness Versus Aflibercept" @default.
- Q89242804 prefLabel "Ranibizumab for the Treatment of Visual Impairment Due to Myopic Choroidal Neovascularization: Cost-Effectiveness Versus Aflibercept" @default.
- Q89242804 prefLabel "Ranibizumab for the Treatment of Visual Impairment Due to Myopic Choroidal Neovascularization: Cost-Effectiveness Versus Aflibercept" @default.
- Q89242804 P1433 Q89242804-F13472D9-13D5-4832-BB37-5102635D659E @default.
- Q89242804 P1476 Q89242804-60E67595-8BD2-458F-965C-0F80D0112191 @default.
- Q89242804 P2093 Q89242804-0BD1827D-D47D-4B99-A444-1DA3B97918FA @default.
- Q89242804 P2093 Q89242804-5F238750-BDD2-4E98-8C4D-857990E01DA9 @default.
- Q89242804 P2093 Q89242804-808DFC47-1117-4B43-9498-19D611DD926D @default.
- Q89242804 P2093 Q89242804-A76DBA0F-2520-4B68-824F-43779EA4CCF3 @default.
- Q89242804 P304 Q89242804-CE54A228-7657-44DC-9BC7-0974D3F1776E @default.
- Q89242804 P31 Q89242804-B650572E-B6D9-487A-93FF-36A65818D426 @default.
- Q89242804 P356 Q89242804-18A56924-0274-4924-A50E-9F0C0C95137F @default.
- Q89242804 P433 Q89242804-72FFF8B4-A41E-4943-AFEE-D4E0062072B7 @default.
- Q89242804 P478 Q89242804-21A4B72A-C0A4-47D4-A4F8-F7E11D2359D4 @default.
- Q89242804 P577 Q89242804-983D0076-ABFE-4414-8086-8FD61053A2E9 @default.
- Q89242804 P698 Q89242804-58B5BA71-AD2D-4EEC-873D-24EA6BCDB718 @default.
- Q89242804 P921 Q89242804-83A144AC-3DE8-4B59-BA40-3C17D8D0655D @default.
- Q89242804 P921 Q89242804-AC1061A9-95CC-466E-BC6C-82D264A9BF68 @default.
- Q89242804 P356 J.JVAL.2014.08.2123 @default.
- Q89242804 P698 27202113 @default.
- Q89242804 P1433 Q15766908 @default.
- Q89242804 P1476 "Ranibizumab for the Treatment of Visual Impairment Due to Myopic Choroidal Neovascularization: Cost-Effectiveness Versus Aflibercept" @default.
- Q89242804 P2093 "C Leteneux" @default.
- Q89242804 P2093 "J Haig" @default.
- Q89242804 P2093 "S Bhattacharyya" @default.
- Q89242804 P2093 "W Xue" @default.
- Q89242804 P304 "A608" @default.
- Q89242804 P31 Q13442814 @default.
- Q89242804 P356 "10.1016/J.JVAL.2014.08.2123" @default.
- Q89242804 P433 "7" @default.
- Q89242804 P478 "17" @default.
- Q89242804 P577 "2014-10-26T00:00:00Z" @default.
- Q89242804 P698 "27202113" @default.
- Q89242804 P921 Q4689286 @default.
- Q89242804 P921 Q737460 @default.